CAPR - Capricor says FDA aligns with path to market lead asset
2023-09-29 09:36:50 ET
More on Capricor
- Capricor: Q4 2023 Interim Analysis For DMD Treatment Makes This A Must Watch
- Capricor Therapeutics, Inc. (CAPR) Q2 2023 Earnings Call Transcript
- Capricor Therapeutics slumps 25%, prices $23M equity
- Seeking Alpha’s Quant Rating on Capricor Therapeutics
- Historical earnings data for Capricor Therapeutics
For further details see:
Capricor says FDA aligns with path to market lead asset